Latest: FDA Approves New Biosimilar for Oncology Treatment

AAIC 2025 Preclinical Results of Anti-Tau Antibody MK-2214 in Alzheimer Disease: Jonathan Sugam, PhD

by Neurology Live

14 September, 2025

0 Mins

The principal scientist of neuroscience discovery at Merck presented preclinical data at AAIC 2025 supporting the development of MK-2214, an anti-tau antibody designed to slow or prevent the progression of AD. [WATCH TIME: 5 minutes]

Tags:

Author

Neurology Live

Navigating Challenges in Pediatric Dermatology Access, Addressing Disparities: Elizabeth Garcia Creighton

Robotic Surgery Exhibits Benefit in Select Colorectal Cancer Procedures

📢

300x250 Banner

AAIC 2025 Preclinical Results of Anti-Tau Antibody MK-2214 in Alzheimer Disease: Jonathan Sugam, PhD

Tags:

Neurology Live

Navigating Challenges in Pediatric Dermatology Access, Addressing Disparities: Elizabeth Garcia Creighton

Robotic Surgery Exhibits Benefit in Select Colorectal Cancer Procedures

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition